For example, Hwang et al. [9] showed in a series of 7230 primary breast cancer patients, that Bcl-2 positivity was associated with better overall survival (HR, 0.42; 95%-CI, 0.42–0.71; p < 0.001), independently of patient age at diagnosis, the histologic grade, tumor size and nodal stage, hormone receptor and HER2 expression, and lymphovascular invasion. This evidence concerns the gene ERBB2 and neoplasm.